NPNapat Prompat

Napat Prompat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Napat Prompat has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Jirakrit Saetang

    International Center of Excellence in Seafood Science and Innovation, Faculty of Agro-Industry, Prince of Songkla University, Hat Yai 90110, Thailand

    5 shared publications
  • Aekkaraj Nualla-Ong

    Division of Biological Science, Faculty of Science, Prince of Songkla University, Songkhla 90110, Thailand

    3 shared publications
  • Niran Roongsawang

    Microbial Cell Factory Research Team, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani 12120, Thailand

    2 shared publications
  • Panik Nadee

    Medical Technology Service Center Faculty of Medical Technology Prince of Songkla University Songkhla 90110 Thailand

    2 shared publications
  • Soottawat Benjakul

    International Center of Excellence in Seafood Science and Innovation, Faculty of Agro-Industry, Prince of Songkla University, Hat Yai, Songkhla, 90110 Thailand

    2 shared publications
  • Surasak Sangkhathat

    Department of Surgery and Translational Medicine Research Center, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110 Thailand; Translational Medicine Research Center, Faculty of Medicine, Prince of Songkla University, Songkhla, 90110, Thailand

    2 shared publications

Latest Publications

  • Open Access

    Impact of Glycine–Serine Linker on Target Antigen Binding and Subsequent CD37CAR-T Performance

    by Wannakorn Khopanlert, Napat Prompat, Jirakrit Saetang, Kajornkiat Maneechai, Shingo Okuno, Seitaro Terakura, Jakrawadee Julamanee

    CD19-chimeric antigen receptor (CAR) has shown promising outcomes in B-cell malignancies. However, relapses due to poor CAR-T persistence and antigen escape have occurred. CD37 is a potential alternative immunotherapy for CD19− tumors. Inferior CAR-T cytotoxicity was observed in CD37CAR-T compared to CD19CAR-T model that was possibly due to lower CD37CAR affinity. To alleviate CD37CAR functions, we optimized the most prevalent linkers, Whitlow (18aaL) and glycine–serine (GS4L). CD37.GS4L CAR-T showed higher transduction efficiency and T-cell expansion contributed by minimizing T-cell fratricide. In chronic antigen stimulation, CD37.GS4L CAR demonstrated robust T-cell proliferation while preserving stemness and a decrease in induced exhaustion phenotype, which resulted in greater tumoricidal activity among various CD37+ malignancies. In silico analysis showed that CD37.GS4L scFv altered structural dynamic behaviors by facilitating variable heavy-chain region closer to CD37 receptor with higher binding affinity and less aggregation of negatively charged protein, which contributed to lower tonic signaling during CAR activation and diminished exhaustion. Ultimately, effective anti-tumor control with notable memory T-cell persistence was exhibited in Burkitt lymphoma mice treated with CD37.GS4L CAR-T. Additionally, CD37.GS4L CAR-T illustrated the potential in vivo cytotoxicity in myeloma-inoculated mice. In summary, the flexibility and affinity of glycine–serine linker of CD37CAR can potentiate CAR-T functionality.

  • QSAR‐Based Machine Learning Reveals a Repurposed Dual‐Function G4 Ligand against Ensitrelvir‐Resistant SARS‐CoV‐2 Main Protease

    by Napat Prompat, Panik Nadee, Aekkaraj Nualla‐Ong

    The emergence of drug‐resistant SARS‐CoV‐2 variants necessitates novel antiviral strategies targeting conserved viral components. This study integrates machine learning‐based quantitative structure‐activity relationship modeling and comprehensive computational approaches to identify dual‐function inhibitors against the main protease and RNA G‐quadruplex structures of SARS‐CoV‐2. A Random Forest classifier trained on 890 curated compounds achieves superior predictive performance (AUC = 0.9458) using CDK fingerprints, enabling virtual screening of 4,564 G‐quadruplex ligands from the G4LDB. Molecular docking reveals lead compound G4L2574 exhibits stronger binding affinity (−12.11 kcal mol −1 ) to the M49I mutant Mpro than clinical inhibitor ensitrelvir (−8.92 kcal mol −1 ), with molecular dynamics simulations demonstrating enhanced complex stability and persistent hydrogen bonding. MM/PBSA calculations confirm favorable binding free energy (−40.54 kcal mol −1 ) for G4L2574‐M49I, driven by robust electrostatic interactions. Structural analysis shows the M49I mutation induced steric hindrance compromising ensitrelvir binding, while G4L2574 maintained critical interactions with catalytic residues His41 and Cys145. Additionally, G4L2574 demonstrates superior RNA G‐quadruplex binding (−11.73 kcal mol −1 ) than RNA G‐quadruplex stabilizing ligand TMPyP4. This dual‐targeting mechanism, validated through machine learning and MD simulations, presents a promising strategy to circumvent resistance mutations while leveraging conserved viral replication targets. The integrated computational pipeline establishes a framework for rapid identification of broad‐spectrum antivirals against evolving coronaviruses.


  • Open Access

    Predicted IL-18/IL-18R Binding Improvement Through Protein Interface Modification with Computer-Aided Design

    by Napat Prompat, Chariya Peeyatu, Jirakrit Saetang, Niran Roongsawang, Surasak Sangkhathat, Varomyalin Tipmanee

    Cytokine-mediated immunotherapy has rapidly emerged as an effective alternative approach for cancer treatment by modulating the anti-tumor response. Interleukin-18 (IL-18) is considered as a promising cancer therapeutic agent due to the ability of cytokines to inhibit cancer by enhancing natural killer (NK) cell and cytotoxic T cell responses. Since the activity of IL-18 is required for the specific binding to IL-18 receptors, the modification of binding residue at the protein interface is an attractive strategy for IL-18 activity enhancement. The aim of this study was to design and predict mutations increasing the activity of IL-18 through computational structure-based energy calculation and molecular dynamic simulations. Four candidate mutations, E6M, E6M+N111S+R131G, E6M+K129M+R131G, and E6M+N111S+K129M+R131G, could affect/facilitate the receptor binding and stability compared to the wild-type via electrostatic interaction. MD simulations demonstrated that the predicted mutation on IL-18 had no influence on the overall conformation stability, but increased flexibility in the β8–β9 hairpin loop. Furthermore, the dynamic behavior suggested that these candidates could be an alternative for the improvement of IL-18 biological activity, though the full simulation of the IL-18 complex remains necessary. In summary, this study offered a computer-aided design strategy which was of beneficial use in the design and development of IL-18 to increase its cytokine potency and efficiency.

  • Identification and characterization of oncogenic KRAS G12V inhibitory peptides by phage display, molecular docking and molecular dynamic simulation

    by Jirakrit Saetang, Montarop Yamabhai, Kuntalee Rangnoi, Napat Prompat, Thaiyawat Haewphet, Surasak Sangkhathat, Varomyalin Tipmanee, Soottawat Benjakul


  • Open Access

    Role of Non-Binding T63 Alteration in IL-18 Binding

    by Chariya Peeyatu, Napat Prompat, Supayang Piyawan Voravuthikunchai, Niran Roongsawang, Surasak Sangkhathat, Pasarat Khongkow, Jirakrit Saetang, Varomyalin Tipmanee

    Engineered interleukin-18 (IL-18) has attracted interest as a cytokine-based treatment. However, knowledge-based mutagenesis of IL-18 has been reported for only a few regions of the protein structures, including binding sites I and II. When coupled with the binding region mutant (E6K), the non-binding residue of IL-18, Thr63 (T63), has been shown to increase the flexibility of the binding loop. Nevertheless, the function of Thr63 in conformational regulation is still unknown. Using homology modeling, molecular dynamics simulation, and structural analysis, we investigated the effects of Thr63 alteration coupling with E6K on conformational change pattern, binding loop flexibility, and the hydrogen bond network. The results indicate that the 63rd residue was significantly associated with hydrogen-bond relaxation at the core β-barrel binding sites I and II Glu85-Ile100 loop. This result provided conformational and flexible effects to binding sites I and III by switching their binding loops and stabilizing the 63rd residue cavity. These findings may pave the way for the conceptualization of a new design for IL-18 proteins by modifying non-binding residues for structure-based drug development.


  • Computational and experimental investigations of a novel aptamer targeting oxidized low-density lipoprotein

    by Soemwit Khongwichit, Aekkaraj Nualla-Ong, Napat Prompat, Maliwan Amatatongchai, Peter A. Lieberzeit, Suticha Chunta


  • In Silico Identification of Selective KRAS G12D Inhibitor via Machine Learning‐Based Molecular Docking Combined with Molecular Dynamics Simulation

    by Panik Nadee, Napat Prompat, Montarop Yamabhai, Surasak Sangkhathat, Soottawat Benjakul, Varomyalin Tipmanee, Jirakrit Saetang

    KRAS G12D mutation is prevalent in various cancers and is associated with poor prognosis. This study aimed to identify potential drug candidates targeting KRAS G12D using combined machine learning, virtual screening, molecular docking, and molecular dynamics (MD) simulations. The training and test sets are constructed based on a selection of inhibitors targeting the KRAS G12D mutant from the ChEMBL library. A random forest machine learning algorithm is developed to predict potential KRAS G12D binders. Molecular docking and the MM/PBSA binding energy are used to identify the lead compounds. The compound NPC489264 is identified as the top candidate, exhibiting favorable docking energy for the KRAS G12D mutant (−13.16 kcal mol−1). A hydrogen bond between the mutated Asp12 residue in the KRAS G12D mutant and NPC489264 is found to be a key interaction between these 2 molecules. MD simulations and MM/PBSA analysis revealed the strong binding affinity of NPC489264 to the G12D mutant (−5.49 kcal mol−1) compared to the wild type (10.17 kcal mol−1). These findings suggest that NPC489264 is a promising lead compound for further development of KRAS G12D‐targeted cancer therapies.